{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32","upperLimit":"86","value":"66"},{"groupId":"OG001","lowerLimit":"47","upperLimit":"96","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"EFS is defined as relapse or treatment-related mortality (TRM). relapse is defined by either morphological or cytogenetic evidence of ALL consistent with pre-transplant features.","dispersionType":"95% Confidence Interval","groups":[{"description":"Conventional bone marrow transplant (BM)","id":"OG000","title":"Control BM Arm"},{"description":"G-CSF (filgrastim) stimulated bone marrow (G-BM)","id":"OG001","title":"Experimental G-BM Arm"}],"paramType":"NUMBER","populationDescription":"Early terminated study. One patient is inevaluable for EFS on experimental arm and is excluded from analysis.","reportingStatus":"POSTED","timeFrame":"at 2 years","title":"Estimated Two-year Event-free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}